Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Belimumab (Benlysta, GSK1550188)

Status:

Phase 3

Condition:

Other ILD

Intervention Type:

Subcutaneous (SC) Injection

Funder Type:

Industry

Drug Details

Belimumab is an Anti-B lymphocyte stimulator (BLys) monoclonal antibody.

Study Purpose

The study will assess whether belimumab, in addition to standard therapy, will result in the stabilization and/or improvement of lung function in participants with interstitial lung disease associated with connective tissue diseases (CTD-ILD).

Find a Clinical Trial